Search

Your search keyword '"Maruyama Satoru"' showing total 229 results
Start Over Author "Maruyama Satoru" Language english
229 results on '"Maruyama Satoru"'

2. Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN

Author

Kato, Takuma, Hirama, Hiromi, Mitsuzuka, Koji, Maruyama, Satoru, Sasaki, Hiroshi, Saito, Toshihiro, Matsumoto, Ryuji, Sakamoto, Shinichi, Sakai, Yasuyuki, Fukuhara, Hiroshi, Naya, Yukio, Tsukino, Hiromasa, Hara, Isao, Ogawa, Osamu, Hashine, Katsuyoshi, Fumimasa, Fukuta, Yokomizo, Akira, Tohi, Yoichiro, Kakehi, Yoshiyuki, and Sugimoto, Mikio

Published
2022
Full Text
View/download PDF

3. Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR

Author

Kobayashi, Takashi, Ito, Katsuhiro, Kojima, Takahiro, Maruyama, Satoru, Mukai, Shoichiro, Tsutsumi, Masakazu, Miki, Jun, Okuno, Tomoya, Yoshio, Yuko, Matsumoto, Hiroaki, Shimazui, Toru, Segawa, Takehiko, Karashima, Takashi, Masui, Kimihiko, Fukuta, Fumimasa, Tashiro, Kojiro, Imai, Kazuto, Suekane, Shigetaka, Nagasawa, Seiji, Higashi, Shin, Fukui, Tomohiro, Ogawa, Osamu, Kitamura, Hiroshi, and Nishiyama, Hiroyuki

Published
2022
Full Text
View/download PDF

4. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching

Author

Nishiyama, Naotaka, Kobayashi, Takashi, Narita, Shintaro, Hidaka, Yu, Ito, Katsuhiro, Maruyama, Satoru, Mukai, Shoichiro, Tsutsumi, Masakazu, Miki, Jun, Okuno, Tomoya, Yoshio, Yuko, Matsumoto, Hiroaki, Shimazui, Toru, Segawa, Takehiko, Karashima, Takashi, Masui, Kimihiko, Fukuta, Fumimasa, Tashiro, Kojiro, Imai, Kazuto, Suekane, Shigetaka, Nagasawa, Seiji, Higashi, Shin, Fukui, Tomohiro, Kojima, Takahiro, Morita, Satoshi, Ogawa, Osamu, Nishiyama, Hiroyuki, and Kitamura, Hiroshi

Published
2022
Full Text
View/download PDF

5. Validation of the Japanese version of the Body Image Scale for bladder cancer patients

Author

Sato, Miho, Osawa, Takahiro, Abe, Takashige, Honda, Michitaka, Higuchi, Madoka, Yamada, Shuhei, Furumido, Jun, Kikuchi, Hiroshi, Matsumoto, Ryuji, Sato, Yasuyuki, Sasaki, Yoshihiro, Harabayashi, Toru, Maruyama, Satoru, Takada, Norikata, Minami, Keita, Tanaka, Hiroshi, Morita, Ken, Kashiwagi, Akira, Murai, Sachiyo, Ito, Yoichi M., Ogasawara, Katsuhiko, and Shinohara, Nobuo

Published
2022
Full Text
View/download PDF

6. Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study

Author

Tohi, Yoichiro, Kato, Takuma, Nakamura, Masaki, Matsumoto, Ryuji, Sasaki, Hiroshi, Mitsuzuka, Koji, Inokuchi, Junichi, Hashine, Katsuyoshi, Yokomizo, Akira, Naito, Hirohito, Hara, Isao, Kawamura, Norihiko, Inoue, Masaharu, Fukuhara, Hiroshi, Maruyama, Satoru, Sakamoto, Shinichi, Saito, Toshihiro, Egawa, Shin, Kakehi, Yoshiyuki, and Sugimoto, Mikio

Published
2022
Full Text
View/download PDF

7. Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study

Author

Tohi, Yoichiro, Kato, Takuma, Yokomizo, Akira, Mitsuzuka, Koji, Tomida, Ryotaro, Inokuchi, Junichi, Matsumoto, Ryuji, Saito, Toshihiro, Sasaki, Hiroshi, Inoue, Koji, Kinoshita, Hidefumi, Fukuhara, Hiroshi, Maruyama, Satoru, Sakamoto, Shinichi, Tanikawa, Toshiki, Egawa, Shin, Ichikura, Haruhiko, Abe, Takashige, Nakamura, Masaki, Kakehi, Yoshiyuki, and Sugimoto, Mikio

Published
2022
Full Text
View/download PDF

10. The usefulness of testosterone administration in identifying false-positive elevation of serum human chorionic gonadotropin in patients with germ cell tumor

Author

Takizawa, Akitoshi, Kawai, Koji, Kawahara, Takashi, Kojima, Takahiro, Maruyama, Satoru, Shinohara, Nobuo, Akamatsu, Shusuke, Kamba, Tomomi, Nakamura, Terukazu, Ukimura, Osamu, Jikuya, Ryosuke, Kishida, Takeshi, Kakimoto, Kenichi, Nishimura, Kazuo, Harabayashi, Toru, Nagamori, Satoshi, Yamashita, Shinichi, Arai, Yoichi, Sawada, Yoshitomo, Sekido, Noritoshi, Kinoshita, Hidefumi, Matsuda, Tadashi, Nakagawa, Tohru, Homma, Yukio, and Nishiyama, Hiroyuki

Published
2017
Full Text
View/download PDF

14. Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy

Author

Hiroshi Kikuchi, Mochizuki Tango, Murakumo Masashi, Takashige Abe, Toru Harabayashi, Tsuchiya Kunihiko, Ataru Sazawa, Nobuo Shinohara, Jun Frumido, Maruyama Satoru, Ishizaki Junji, Miyajima Naoto, Takahiro Osawa, Sachiyo Murai, Haruka Miyata, Ryuji Matsumoto, Akino Tomoshige, Chiba Satoshi, Hiroki Chiba, and Keita Minami

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Metastatic Urothelial Carcinoma, medicine.medical_treatment, 030232 urology & nephrology, chemotherapy, surgery, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Survival analysis, radiotherapy, Performance status, Proportional hazards model, business.industry, Hazard ratio, General Medicine, Chemotherapy regimen, Radiation therapy, 030220 oncology & carcinogenesis, metastatic urothelial carcinoma, Metastasectomy, business
Abstract

Objective To clarify the prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients treated by systemic chemotherapy. Methods Of the 228 metastatic urothelial carcinoma patients treated with systemic chemotherapy, 97 received radiotherapy mainly to metastatic sites. In patients for whom the purpose of radiotherapy was not specified, more than 50 Gy irradiation was considered to be for disease consolidation for survival analysis, while less than 50 Gy was categorized as palliation. According to the Kaplan–Meier method, we analysed overall survival from the initiation of treatment for metastatic urothelial carcinoma until death or the last follow-up, using the log-rank test to assess the significance of differences. The Cox model was applied for prognostic factor analysis. Results Overall, there was no significant difference in survival between patients with and those without radiotherapy (P = 0.1532). When analysing the patients undergoing consolidative radiotherapy separately, these 25 patients showed significantly longer survival than the 72 patients with palliative radiotherapy (P = 0.0047), with a 3-year overall survival of 43.3%. Of the present cohort, 22 underwent metastasectomy for disease consolidation, and there was no overlapping case between the metastasectomy cohort and cohort receiving consolidative radiotherapy. After controlling for four independent prognostic factors (sex, performance status, haemoglobin level and number of organs with metastasis) in our previous study, radiotherapy for disease consolidation showed a marginal value (hazard ratio = 0.666, P = 0.0966), while metastasectomy remained significant (hazard ratio = 0.358, P = 0.0006). Conclusions In the selected patients, long-term disease control could be achieved after consolidative radiotherapy for metastatic urothelial carcinoma disease. Our observations suggest that local ablative therapy (surgery or radiotherapy) could facilitate long-term disease control. However, the treatment decision should be individualized because of the lack of randomized control trials.

Published
2020

18. Particle therapy for prostate cancer: The past, present and future

Author

Ishikawa, Hitoshi, Tsuji, Hiroshi, Murayama, Shigeyuki, Sugimoto, Mikio, Shinohara, Nobuo, Maruyama, Satoru, Murakami, Motohiro, Shirato, Hiroki, Sakurai, Hideyuki, and Hiroshi, Tsuji

Abstract

Although prostate cancer control using radiotherapy is dose-dependent, dose–volume effects on late toxicities in organs at risk, such as the rectum and bladder, have been observed. Both protons and carbon ions offer advantageous physical properties for radiotherapy, and create favorable dose distributions using fewer portals compared with photon-based radiotherapy. Thus, particle beam therapy using protons and carbon ions theoretically seems suitable for dose escalation and reduced risk of toxicity. However, it is difficult to evaluate the superiority of particle beam radiotherapy over photon beam radiotherapy for prostate cancer, as no clinical trials have directly compared the outcomes between the two types of therapy due to the limited number of facilities using particle beam therapy. The Japanese Society for Radiation Oncology organized a joint effort among research groups to establish standardized treatment policies and indications for particle beam therapy according to disease, and multicenter prospective studies have been planned for several common cancers. Clinical trials of proton beam therapy for intermediate-risk prostate cancer and carbon-ion therapy for high-risk prostate cancer have already begun. As particle beam therapy for prostate cancer is covered by the Japanese national health insurance system as of April 2018, and the number of facilities practicing particle beam therapy has increased recently, the number of prostate cancer patients treated with particle beam therapy in Japan is expected to increase drastically. Here, we review the results from studies of particle beam therapy for prostate cancer and discuss future developments in this field.

Published
2019

23. Immune‐related adverse events in urothelial cancer patients: Adjustment for immortal time bias.

Author

Otsuka, Hikari, Kita, Yuki, Ito, Katsuhiro, Sano, Takeshi, Inokuchi, Junichi, Tomida, Ryotaro, Takahashi, Atsushi, Matsumoto, Kazumasa, Kurahashi, Ryoma, Ozaki, Yu, Uegaki, Masayuki, Maruyama, Satoru, Mukai, Shoichiro, Tsutsumi, Masakazu, Kawahara, Takashi, Segawa, Takehiko, Kitamura, Hiroshi, Morita, Satoshi, and Kobayashi, Takashi

Abstract

To investigate the association between the onset, severity, and type of immune‐related adverse events (irAEs) and the efficacy of pembrolizumab in patients with platinum‐pretreated advanced urothelial carcinoma (UC), we retrospectively collected clinical datasets of 755 patients and conducted landmark analysis. Patients who survived for fewer than 3 months were excluded from the evaluation to reduce the immortal time bias. In total, 620 patients were evaluated, of whom 220 patients (35.5%) experienced grade ≥2 irAEs, including 134 patients with grade 2 irAEs and 86 with grade ≥3 irAEs. Propensity score matching extracted 198 patients with and without grade ≥2 irAEs. The onset of grade ≥2 irAEs was associated with longer median progression‐free survival (PFS) (8.3 months vs. 4.5 months, p = 0.003) and overall survival (OS) (20.4 months vs. 14.3 months, p = 0.031) and a higher objective response rate (ORR) (44.8% vs. 30.2%, p = 0.004). Patients with grade 2 irAEs had significantly better oncological outcomes (PFS, OS, and ORR) than grade ≤1 and ≥3 irAEs. Patients with grade ≥3 irAEs had worse outcomes than grade 2 irAEs. Endocrine and skin irAEs were related with better survival outcomes, and the rate of severities was lower in these categories. In conclusion, the occurrence of irAEs, particularly low‐grade irAEs, was predictive of pembrolizumab efficacy in patients with platinum‐pretreated advanced UC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

29. Quality improvement in managing patients with non-muscle-invasive bladder cancer by introducing a surgical checklist for transurethral resection of bladder tumor.

Author

Kikuchi, Hiroshi, Osawa, Takahiro, Abe, Takashige, Matsumoto, Ryuji, Maruyama, Satoru, Murai, Sachiyo, and Shinohara, Nobuo

Subjects
CANCER invasiveness, BLADDER cancer, PROSTATE, PROPORTIONAL hazards models, TUMOR surgery, LOG-rank test, TRANSURETHRAL resection of bladder
Abstract

Background: The quality of transurethral resection of bladder tumor (TURBT) markedly varies among surgeons and may have a considerable impact on treatment outcomes. The importance of a surgical checklist for TURBT has been suggested in order to standardize the procedure and improve surgical and oncological outcomes. In the present study, we verified the usefulness of a checklist for managing patients with non-muscle-invasive bladder cancer (NMIBC). Methods: This retrospective study included 201 NMIBC patients diagnosed with Ta, T1, or Tis between October 2011 and February 2021. After September 2016, TURBT was performed with a checklist. We analyzed the intravesical recurrence-free survival (RFS) rate and the presence or absence of the detrusor muscle in resected specimens before and after the introduction of the checklist. Survival rates were compared using the Log-rank test. A multivariate analysis with Cox proportional hazards modeling was performed to verify risk factors for intravesical recurrence. Results: Ninety-nine patients who underwent TURBT with the checklist (checklist group) were compared with 102 patients who underwent TURBT without the checklist (non-checklist group). When the analysis was narrowed down to 9 critical items, we observed a mean number of 9 documented items per operative report (98.0% completion) after implementation of the checklist. Two-year intravesical RFS rates in the checklist and non-checklist groups were 76.7 and 69.5%, respectively (p = 0.1059). The Cox proportional multivariate analysis showed that the rate of intravesical recurrence was slightly lower in the checklist group (hazard ratio 0.7376, 95% CI 0.4064–1.3388, P = 0.3170). Conclusion: The introduction of a checklist is recommended for the standardization of TURBT and increasing the quality of operative reporting, and it may also improve oncological outcomes. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study.

Author

Tohi, Yoichiro, Kato, Takuma, Miyakawa, Jimpei, Matsumoto, Ryuji, Sasaki, Hiroshi, Mitsuzuka, Koji, Inokuchi, Junichi, Matsumura, Masafumi, Yokomizo, Akira, Kinoshita, Hidefumi, Hara, Isao, Kawamura, Norihiko, Hashimoto, Kohei, Inoue, Masaharu, Teishima, Jun, Kanno, Hidenori, Fukuhara, Hiroshi, Maruyama, Satoru, Sakamoto, Shinichi, and Saito, Toshihiro

Published
2022
Full Text
View/download PDF

35. Peri-operative morbidity and mortality related to radical cystectomy: a multi-institutional retrospective study in Japan

Author

Takada, Norikata, Abe, Takashige, Shinohara, Nobuo, Sazawa, Ataru, Maruyama, Satoru, Shinno, Yuichiro, Sato, Soshu, Mitsuhashi, Kimiyoshi, Sato, Takuya, Sugishita, Keiji, Kamota, Shinji, Yamashita, Takanori, Ishizaki, Junji, Hioka, Takaya, Mouri, Gaku, Ono, Takenori, Miyajima, Naoto, Sakuta, Takanori, Mochizuki, Tango, Aoyagi, Toshiki, Katano, Hidenori, Akino, Tomoshige, Hirakawa, Kazushi, Minami, Keita, Kumagai, Akira, Seki, Toshimori, Togashi, Masaki, and Nonomura, Katsuya

Published
2012
Full Text
View/download PDF

42. Outcomes of bacillus Calmette–Guérin therapy without a maintenance schedule for high‐risk non‐muscle‐invasive bladder cancer in the second transurethral resection era.

Author

Kikuchi, Hiroshi, Abe, Takashige, Matsumoto, Ryuji, Osawa, Takahiro, Maruyama, Satoru, Murai, Sachiyo, and Shinohara, Nobuo

Subjects
BLADDER cancer, CANCER invasiveness, URETHRA, PROPORTIONAL hazards models, PROGRESSION-free survival, TUMOR classification, MULTIPLE tumors
Abstract

Objectives: We examined the outcomes of eight weekly bacillus Calmette–Guérin induction therapy after second transurethral resection, and investigated risk factors for intravesical recurrence or disease progression in high‐risk non‐muscle‐invasive bladder cancer patients. Methods: This retrospective study included 146 high‐risk non‐muscle‐invasive bladder cancer patients who received eight weekly bacillus Calmette–Guérin instillations without a maintenance schedule between 2000 and 2019. Intravesical recurrence‐free and progression‐free survival rates were evaluated using the Kaplan–Meier method. The Cox proportional hazards model was used to identify risk factors. Results: Pathological T staging in the first transurethral resection was pTa in 56 patients (38.4%), pT1 in 75 (51.4%) and primary carcinoma in situ in 15 (10.2%). A total of 109 (83.2%) with pTa–1 disease underwent second transurethral resection before bacillus Calmette–Guérin induction therapy, and residual disease was detected in 54 (49.5%). The completion rate of eight instillations was 82.2%. The 2‐ and 5‐year intravesical recurrence‐free survival rates were 80.7% and 75.2%, whereas the 2‐ and 5‐year progression‐free survival rates were 85.7% and 82.0%. Recurrent tumors (hazard ratio 6.5830, P = 0.0007) and residual tumors at the second transurethral resection (hazard ratio 4.0337, P = 0.0021) were risk factors for intravesical recurrence. Multiple tumors (hazard ratio 5.8056, P = 0.0302), pT1 disease (hazard ratio 3.7351, P = 0.0447) and residual tumors at second transurethral resection (hazard ratio 3.2552, P = 0.0448) were associated with disease progression. Conclusions: Accurate disease staging and disease elimination by second transurethral resection followed by eight weekly bacillus Calmette–Guérin instillations achieved good disease control. Our protocol (without a maintenance schedule) after thorough surgical resection has potential as a treatment option in the current bacillus Calmette–Guérin shortage. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. MP78-20 THE MODIFIED GLASGOW PROGNOSTIC SCORE IS A POWERFUL PROGNOSTIC FACTOR IN METASTATIC UROTHELIAL CARCINOMA PATIENTS RECEIVING SECOND-LINE CHEMOTHERAPY

Author

Matsumoto, Ryuji, Abe, Takashige, Ishizaki, Junji, Minami, Keita, Harabayashi, Toru, Sazawa, Ataru, Mochizuki, Tango, Akino, Tomoshige, Murakumo, Masashi, Miyajima, Naoto, Tsuchiya, Kunihiko, Kikuchi, Hiroshi, Miyata, Haruka, Osawa, Takahiro, Maruyama, Satoru, Murai, Sachiyo, and Shinohara, Nobuo

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results